logo-loader
viewAllergy Therapeutics PLC

Allergy Therapeutics hopes to launch "exciting" grass pollen allergy vaccine in 2019

Tim Higenbottam, R&D director at hay fever vaccine specialist Allergy Therapeutics (LON:AGY) tells Proactive Investors GrassMATAMPL is one of its two most advanced products in development.
He hopes the company will be in a position to start phase III studies at some point this year.
The company aims to launch the ground-breaking and "exciting" grass pollen allergy treatment in 2019 after all the trials are completed and the treatment is approved.

Quick facts: Allergy Therapeutics PLC

Price: 13.555 GBX

AIM:AGY
Market: AIM
Market Cap: £86.38 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Allergy Therapeutics PLC named herein, including the promotion by the Company of Allergy Therapeutics PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Allergy Therapeutics shares tipped to rise to 32p

Allergy Therapeutics plc (LON:AGY) has a chance of rising to around 32p per share, so says technical analyst Zak Mir. In a Tip TV segment for Proactive Investors, Mir highlights the big turnaround in the chart for Allergy Therapeutics and notes that it is now in a rising trend.

on 02/21/2017

2 min read